Ligand validation:8UEC

16C: N-((E,2S,3R)-1,3-DIHYDROXYOCTADEC-4-EN-2-YL)PALMITAMIDE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8UEC_16C_A_401	1%	27%	0.289	0.474	1.64	1.29	5	3	2	0	100%	1
6W8F_16C_A_403	26%	33%	0.223	0.866	1.62	1.05	5	1	0	0	100%	1
6CQ8_16C_A_407	12%	44%	0.217	0.75	1.16	1	3	2	10	0	100%	1
8UF6_16C_B_409	10%	33%	0.2	0.699	1.58	1.07	5	2	0	0	100%	1
6CQ9_16C_A_406	9%	44%	0.215	0.706	1.1	1.08	2	2	2	0	100%	1
6W8A_16C_A_404	6%	33%	0.25	0.688	1.62	1.05	5	1	0	0	100%	1
2OSX_16C_A_603	69%	74%	0.078	0.971	0.4	0.62	-	-	0	0	55%	0.5526
2E3P_16C_B_700	52%	69%	0.136	0.894	0.46	0.73	-	1	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.